Analyst Price Targets — ZVRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 27, 2026 11:16 am | — | Guggenheim | $24.00 | $9.53 | TheFly | Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim |
| July 27, 2026 11:05 am | Kambiz Yazdi | BTIG | $24.00 | $9.53 | TheFly | Zevra Therapeutics price target lowered to $24 from $27 at BTIG |
| July 27, 2026 10:30 am | Sumant Kulkarni | Canaccord Genuity | $20.00 | $9.53 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $20 at Canaccord |
| June 10, 2026 5:32 pm | Jason McCarthy | Maxim Group | $35.00 | $13.67 | TheFly | Zevra Therapeutics price target raised to $35 from $25 at Maxim |
| June 10, 2026 10:52 am | Eddie Hickman | Guggenheim | $29.00 | $13.66 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Guggenheim |
| June 9, 2026 10:50 am | Sumant Kulkarni | Canaccord Genuity | $29.00 | $12.09 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Canaccord |
| May 8, 2026 11:15 am | Eddie Hickman | Guggenheim | $25.00 | $11.00 | TheFly | Zevra Therapeutics price target raised to $25 from $23 at Guggenheim |
| March 10, 2026 10:40 am | Eddie Hickman | Guggenheim | $23.00 | $11.03 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim |
| December 30, 2025 11:38 am | Brandon Folkes | H.C. Wainwright | $26.00 | $8.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA) |
| November 6, 2025 2:04 pm | Kristen Kluska | Cantor Fitzgerald | $24.00 | $9.29 | TheFly | Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald |
Latest News for ZVRA
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.
BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of…
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the…
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZVRA.
U.S. House Trading
No House trades found for ZVRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.